Jerasimos Ballas

Jerasimos Ballas

Auto-generated profile, based on publicly available information

Jerasimos Ballas

School of Medicine, Obstetrics, Gynecology and Reproductive Sciences (Ballas), University of Calfornia San Diego, La Jolla, CA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Open access
DMDora J. Melber
Dora J. Melber
ZBZachary T Berman
Zachary T Berman
MJMarni B. Jacobs
Marni B. Jacobs
APAndrew C. Picel
Andrew C. Picel
CCCharlotte L. Conturie
Charlotte L. Conturie
TKThomas F. Kelly
Thomas F. Kelly
Multidisciplinary care of placenta accreta spectrum cases improves pregnancy outcomes, but the specific components of such a multidisciplinary collaboration varies between institutions. As experience with placenta accreta spectrum increases, it is crucial to assess new surgical techniques and protocols to help improve maternal outcomes and to advocate for hospital resources. This study aimed to assess a novel multidisciplinary protocol for the treatment of placenta accreta spectrum that comprises cesarean delivery, multivessel uterine embolization, and hysterectomy in a single procedure within a hybrid operative suite. This was a matched prepost study of placenta accreta spectrum cases managed before (2010-2017) and after implementation of the Placenta Accreta Spectrum Treatment With Intraoperative Multivessel Embolization protocol (2018-2021) at a tertiary medical center. Historical cases were managed with internal iliac artery balloon placement in selected cases with the decision to inflate the balloons intraoperatively at the discretion of the primary surgeon. Intraoperative Embolization cases were compared with historical cases in a 1:2 ratio matched on the basis of placenta accreta spectrum severity and surgical urgency. The primary outcome was a requirement for transfusion with packed red blood cells. Secondary outcomes included estimated surgical blood loss, operative and postoperative complications, procedural time, length of stay, and neonatal outcomes. A total of 15 Placenta Accreta Spectrum Treatment With Intraoperative Multivessel Embolization cases and 30 matched historical cases were included in the analysis. There were no demographic differences noted between the groups. A median (interquartile range) of 0 units (0-2 units) of packed red blood cells were transfused in the Intraoperative Embolization group compared with 2 units (0-4.5 units) in the historical group (P=.045); 5 of 15 (33.3%) Intraoperative Embolization cases required blood transfusions compared with 19 of 30 (63.3%) cases in the historical group (P=.11). The estimated blood loss was significantly less in the Intraoperative Embolization group with a median (interquartile range) of 750 mL (450-1050 mL) compared with 1750 mL (1050-2500 mL) in the historical group (P=.003). There were no cases requiring massive transfusion (≥10 red blood cell units in 24 hours) in the Intraoperative Embolization group compared with 5 of 30 (16.7%) cases in the historical group (P=.15). There were no intraoperative deaths from hemorrhagic shock using the Intraoperative Embolization protocol, whereas this occurred in 2 of the historical cases. The mean duration of the interventional radiology procedure was longer in the Intraoperative Embolization group (67.8 vs 34.1 minutes; P=.002). Intensive care unit admission and postpartum length of stay were similar, and surgical and postoperative complications were not significantly different between the groups. The gestational age and neonatal birthweights were similar; however, the neonatal length of stay was longer in the Intraoperative Embolization group (median duration, 32 days vs 15 days; P=.02) with a trend toward low Apgar scores. Incidence of arterial umbilical cord blood pH <7.2 and respiratory distress syndrome and intubation rates were not statistically different between the groups. A multidisciplinary pathway including a single-surgery protocol with multivessel uterine embolization is associated with a decrease in blood transfusion requirements and estimated blood loss with no increase in operative complications. The Placenta Accreta Spectrum Treatment With Intraoperative Multivessel Embolization protocol provides a definitive surgical method that warrants consideration by other centers specializing in placenta accreta spectrum treatment.

2 August 2021 in Alcohol, Clinical and Experimental Research
Verified
Journal Article
Closed access
PDF file
NCNatasia S. Courchesne
Natasia S. Courchesne
LSLaramie R. Smith
Laramie R. Smith
MZMaría Luisa Zúñiga
María Luisa Zúñiga
CCChristina D Chambers
Christina D Chambers
MRMark B. Reed
Mark B. Reed
CMCarla B. Marienfeld
Carla B. Marienfeld

30 July 2023 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
ZBZachary T Berman
Zachary T Berman
CBChristine E. Boone
Christine E. Boone
DMDora J. Melber
Dora J. Melber
JBJerasimos Ballas
Jerasimos Ballas
RPRupal Parikh
Rupal Parikh
ARAnne C. Roberts
Anne C. Roberts

28 June 2022 in Journal of Addictive Diseases
Verified
Journal Article
Closed access
NCNatasia S. Courchesne-Krak
Natasia S. Courchesne-Krak
MZMaría Luisa Zúñiga
María Luisa Zúñiga
CCChristina D Chambers
Christina D Chambers
MRMark B. Reed
Mark B. Reed
LSLaramie R. Smith
Laramie R. Smith
CMCarla Marienfeld
Carla Marienfeld
This article aimed to evaluate whether a substance-related diagnosis (SRD; i.e., alcohol, opioids, cannabis, stimulants, nicotine) predicts the likelihood and co-occurrence of preterm (20–37 weeks’...

17 April 2026 in American Journal of Obstetrics & Gynecology MFM
Verified
Journal Article
Open access
RRRita Ryu
Rita Ryu
CPCatherine Psaras
Catherine Psaras
RBRebecca J. Baer
Rebecca J. Baer
KPKristin Palmsten
Kristin Palmsten
JTJeanne Townsend
Jeanne Townsend
GBGretchen Bandoli
Gretchen Bandoli
Women with intellectual disabilities have a higher prevalence of chronic health conditions and behavioral risk factors, yet the extent to which these factors contribute to adverse maternal outcomes is unclear. To identify and prioritize intervention targets to reduce severe maternal morbidity and hypertensive disorders of pregnancy among women with intellectual disabilities. We conducted a population-based cohort study linking 2007-2020 California birth and fetal death records with hospital discharge, emergency department, and ambulatory surgery data. Among 6,099,797 singleton births, including 1114 women with intellectual disabilities, we created a 1:30 matched cohort of women with and without intellectual disabilities, matched on age, birth year, race/ethnicity, payer type, participation in the Supplemental Nutrition Program for Women, Infants, and Children, and maternal nativity. Intellectual disability and outcomes were identified from International Classification of Diseases codes at delivery. We used generalized linear modeling to estimate risk differences, risk ratios, and respective 95% confidence intervals for the association between intellectual disabilities and adverse maternal outcomes including severe maternal morbidity, preeclampsia, and gestational hypertension. We performed regression-based joint and single mediation analyses to assess the contribution of selected mediators to the association between intellectual disabilities and these adverse maternal outcomes. Women with intellectual disabilities were younger [26.8 (SD=5.9) vs 29.0 (SD=6.2) years] and more likely to be non-Hispanic Black (19% vs 5%), have public payer for delivery (82% vs 48%), participate in nutrition assistance (79% vs 50%), and be born in the US (92% vs 80%). In the adjusted matched analytic sample, women with intellectual disabilities (n=1107) were more likely to have inadequate prenatal care (40% vs 29%), substance use disorders during pregnancy (11%-16% vs 3%-6%) and mental health conditions (12%-16% vs 2%) compared to women without intellectual disabilities (n=33,174). Additionally, they were more likely to have chronic comorbidities including respiratory conditions (19% vs 6%), epilepsy (12% vs 1%), preexisting hypertension (7% vs 3%), preexisting diabetes (7% vs 1%), or hyperthyroidism or hypothyroidism (4% vs 1%). Compared to those without intellectual disabilities, women with intellectual disabilities had an adjusted excess risk per 100 deliveries was 3.0 for severe maternal morbidity (95% CI: 1.8, 4.4), 7.8 for preeclampsia (95% CI: 5.8, 9.7), and 6.9 for gestational hypertension (95% CI: 4.8, 9.0). Corresponding adjusted risk ratio was 2.7 (95% CI: 2.1, 3.5) for severe maternal morbidity, 2.8 (95% CI: 2.3, 3.3) for preeclampsia, 2.0 (95% CI: 1.7, 2.3) for gestational hypertension. Jointly, all mediators with sufficient frequencies explained 29.1% (95% CI: 15.9, 50.3) of the association between intellectual disability and severe maternal morbidity, 37.6% (95% CI: 27.6, 52.0) for preeclampsia, and 25.4% (95% CI: 5.8, 47.8) for gestational hypertension. In single-mediator analyses, epilepsy accounted for the greatest proportion of the total effect for severe maternal morbidity (11%), preexisting hypertension was the strongest mediator for preeclampsia (16%), and anxiety showed the highest proportion mediated for gestational hypertension (21%). Chronic comorbidities and behavioral risk factors accounted for roughly one-quarter to one-third of the increased risks of severe maternal morbidity and hypertensive disorders of pregnancy among women with intellectual disabilities. These findings highlight opportunities for targeted preconception and prenatal interventions to improve maternal health equity.

1 September 2012 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
PSPatrice Sutton
Patrice Sutton
TWTracey J. Woodruff
Tracey J. Woodruff
JPJoanne Perron
Joanne Perron
NSNaomi E. Stotland
Naomi E. Stotland
JCJeanne A. Conry
Jeanne A. Conry
RORy Oa
Ry Oa